Abstract 4103
Background
Obesity is an established risk factor for colorectal cancer (CRC), however little is known about the impact on survival of changes in body composition during chemotherapy.
Methods
A prospective study of adult CRC patients undergoing chemotherapy between 2012-2016 was conducted. Baseline body composition and longitudinal changes were examined using computed tomography (CT) images at two timepoints (interval 7 months, IQR:5-9 months) using paired t-tests. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates –age, sex, performance status & systemic inflammation.
Results
In total, 268 patients were recruited (66% male, mean age 63 years) and 51% were undergoing chemotherapy with a palliative intent. At baseline, 4% had BMI <20 kg/m2 & 58% had BMI ≥25 kg/m2. However, 38%, 34% & 43% had cachexia, sarcopenia & low MA, respectively. Over 100 days, 68% were muscle stable (±1 kg), while 25% lost >1 kg and 7% gained >1 kg. Fat mass remained stable ±1 kg in 49%, while 28% lost >1 kg and 23% gained >1 kg. On multivariate analysis, baseline BMI and subcutaneous fat (SAT) loss predicted survival in patients treated with palliative intent. Normal BMI (20-25kg/m2) predicted reduced survival compared to overweight (25-30kg/m2) [HR:1.80 (95% CI:1.04–3.14), p = 0.037]. Loss of > 6.4% SAT over 100 days was predictive of poor survival versus gain/<6.4% loss, independent of changes in muscle mass [HR:2.2 (95% CI:1.07–4.62), p = 0.033].
Conclusions
Patients with CRC experience significant losses in muscle and fat mass during chemotherapy. Loss of SAT mass during palliative chemotherapy is prognostic of poor survival, independent of changes in muscle mass. Baseline BMI in the overweight range confers a survival advantage. Nutritional strategies to prevent or attenuate weight loss during chemotherapy are advisable especially in the context of advanced CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Breakthrough Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3006 - Nal-iri/lv5-fu versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.
Presenter: Violaine Randrian
Session: Poster Display session 2
Resources:
Abstract
3697 - The expression of Versican and its role in pancreatic neuroendocrine tumor
Presenter: Zhao Sun
Session: Poster Display session 2
Resources:
Abstract
6073 - Characteristics of patients with thyroid carcinoma in the united states
Presenter: Dina El-Habashy
Session: Poster Display session 2
Resources:
Abstract
2124 - The discrimination of pituitary adenomas and craniopharyngioma on MRI: from image features to texture features
Presenter: Hanyue Xu
Session: Poster Display session 2
Resources:
Abstract
3786 - Proportion of Peripheral Lymphocyte Subsets Correlates with the Progression-free Survival and Metastatic Status of Pancreatic Neuroendocrine Tumor Patients
Presenter: Yitao Gong
Session: Poster Display session 2
Resources:
Abstract
2263 - Immunohistochemical expression of ER-α and PR in papillary thyroid carcinoma
Presenter: Enas Elkhouly
Session: Poster Display session 2
Resources:
Abstract
4386 - SILVELUL Project: Immunohistochemical panel analyses as potential predictive and prognostic factors in Pancreatic Neuroendocrine Tumors (PanNET) Treated with CAPTEM or Everolimus
Presenter: Ana De Jesus-Acosta
Session: Poster Display session 2
Resources:
Abstract
2302 - Carcinoid heart disease (CHD): the CRUSOE-NETs, a prospective cohort study from the French Group of Endocrine Tumors (GTE)
Presenter: Kathleen Dekeister Geoffroy
Session: Poster Display session 2
Resources:
Abstract
5749 - Safety of high doses of somatostatin analogs in well differentiated NENs in elderly
Presenter: Massimiliano Cani
Session: Poster Display session 2
Resources:
Abstract
3931 - Differences in multikinase inhibitors (MKI) toxicity profile according to gender. A pooled analysis of three phase II trials with lenvatinib, pazopanib and sorafenib in patients (pts) with advanced gastroenteropancreatic (GEP) neuroendocrine tumors (NETs).
Presenter: Jorge Hernando Cubero
Session: Poster Display session 2
Resources:
Abstract